(
Figure(2:(
(
(
((
References:(
1.!! Neelapu! SS,! Locke! FL,! Bartlett! NL,! et! al.! Axicabtagene! Ciloleucel! CAR! T>Cell! Therapy! in!
Refractory!Large!B>Cell!Lymphoma.!N!Engl!J!Med!2017;377(26):2531–44.!!
2.!! Locke! FL,! Ghobadi! A,! Jacobson! CA,! et! al.! Long>term! safety! and! activity! of! axicabtagene!
ciloleucel!in!refractory!large!B>cell!lymphoma!(ZUMA>1):!a!single>arm,!multicentre,!phase!1–2!
trial.!Lancet!Oncol!2019;20(1):31–42.!!
3.!! Schuster!SJ,!Bishop!MR,!Tam!CS,!et!al.!Tisagenlecleucel!in!adult!relapsed!or!refractory!diffuse!
large!B>cell!lymphoma.!N!Engl!J!Med!2019;380(1):45–56.!!
4.!! Abramson! JS,! Palomba! ML,! Gordon! LI,! et! al.! Lisocabtagene! maraleucel! for! patients! with!
relapsed!or!refractory!large!B>cell!lymphomas!(TRANSCEND!NHL!001):!a!multicentre!seamless!
design!study.!Lancet!2020;396(10254):839–52.!!
5.!! Lee! DW,! Santomasso! BD,! Locke! FL,! et! al.! ASTCT! Consensus! Grading! for! Cytokine! Release!
Syndrome!and!Neurologic!Toxicity!Associated!with!Immune!Effector!Cells.!Biol!Blood!Marrow!
Transplant!2019;25(4):625–38.!!
!
! !